Target intelligence / Profile preview

Herpesvirus glycoprotein B (gB)

Target
gB
Molecular classification
Viral fusion protein, Envelope glycoprotein, Class III viral fusion protein[2][7]
01

Overview

Herpesvirus glycoprotein B (gB) is a highly conserved envelope protein found on all herpesviruses, including Herpes simplex virus type 1 (HSV‑1). It is a type I transmembrane protein that forms trimeric spikes on the viral envelope. As an essential component of the "core fusion machinery," along with other viral proteins such as gD and the gH/gL complex, gB mediates the critical step of fusing the viral envelope with host cell membranes during entry. The structure consists of five domains with specialized functions—domain I contains internal fusion loops that insert into cellular membranes; domain II interacts with other viral proteins; domain IV may interact with cellular receptors. The transition between prefusion and postfusion conformations enables membrane merger but also complicates immune recognition. Neutralizing antibodies targeting multiple domains can block infection by interfering with these processes. Due to its central role in infectivity and immunogenicity, gB is a major target for vaccine development and antiviral research against herpesvirus infections[2][3][4].

Other names
Glycoprotein BHSV gBHHV-1 gBEnvelope glycoprotein B
02

Mechanism of action

Inhibition of virus-cell membrane fusion (by neutralizing antibodies or experimental inhibitors)[3][4]

03

Biological functions

Virus-cell membrane fusion[2][4]Viral entry into host cells[2][4]Induction of neutralizing antibody response[3][7]
04

Disease associations

Infection (Herpes simplex virus infection and other herpesviruses)[2][3][4]
05

Safety considerations

Potential for immune evasion due to conformational changes masking key epitopes from the host immune system; challenges in vaccine design due to structural dynamics of the prefusion/postfusion states[7].
06

Interacting drugs

No approved small-molecule drugs directly target gB in clinical use as of 2024; however, monoclonal antibodies and experimental fusion inhibitors are under investigation[4].
07

Biomarkers

Anti-gB antibody titers can serve as biomarkers for HSV infection and immune response monitoring[3].

Beyond the preview

Go deeper on Herpesvirus glycoprotein B (gB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Herpesvirus glycoprotein B (gB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call